Department of Radiology, Beppu Hospital, Kyushu University, Beppu, Japan.
Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
PLoS One. 2021 Sep 7;16(9):e0256471. doi: 10.1371/journal.pone.0256471. eCollection 2021.
Most small renal cell carcinomas (small RCCs) will remain indolent after detection, but some stage I RCCs still metastasize. There are no risk-stratification imaging factors that could be used to identify poor-prognosis patients based on genomic profiling. Here, we evaluated the relationships between imaging parameters and RNA expressions in small RCC and attempted to identify imaging factors that could be used as effective biomarkers.
We acquired biopsy specimens of 18 clear cell carcinomas that had undergone perfusion CT (pCT) and MRI between April 2018 and March 2019. We performed RNA sequencing, assessed RNA expressions, and calculated each tumor's cell-cycle progression (CCP) score, which has prognostic value in predicting metastatic progression. We classified the tumors into two groups: clear cell type A (ccA) and type B (ccB). CcA has better survival compared to ccB. We evaluated the following characteristics of each tumor: tumor size, presence of pseudocapsule, and fat. We used the pCT and MRI to measure each tumor's volume transfer constant (Ktrans), rate constant (Kep), extracellular extravascular volume fraction (VE), fractional plasma volume (VP), and apparent diffusion coefficient (ADC). The correlations between these small RCC imaging parameters and the tumor size and RNA expressions were determined.
The tumor size was significantly correlated with Kep and inversely correlated with VE, VP, ADC, and hallmark angiogenesis. The CCP score was significantly inversely correlated with Ktrans and Kep. The ccA tumors tended to show a pseudocapsule on MRI.
Tumor size was correlated with low perfusion, but not with prognostic factors based on genomic profiling. Imaging parameters (e.g., Ktrans and Kep) and tumor characteristics (e.g., pseudocapsule) may enable gene-based risk stratification in small RCC.
大多数小肾细胞癌(small RCC)在发现后仍处于惰性状态,但一些 I 期肾细胞癌仍会转移。目前尚无可用于根据基因组分析识别预后不良患者的风险分层成像因素。在此,我们评估了小肾细胞癌的影像学参数与 RNA 表达之间的关系,并试图确定可作为有效生物标志物的影像学因素。
我们获取了 18 例在 2018 年 4 月至 2019 年 3 月期间接受灌注 CT(pCT)和 MRI 检查的透明细胞癌的活检标本。我们进行了 RNA 测序,评估了 RNA 表达,并计算了每个肿瘤的细胞周期进展(CCP)评分,该评分对预测转移进展具有预后价值。我们将肿瘤分为两类:透明细胞 A 型(ccA)和 B 型(ccB)。与 ccB 相比,ccA 具有更好的生存。我们评估了每个肿瘤的以下特征:肿瘤大小、假包膜的存在和脂肪。我们使用 pCT 和 MRI 测量每个肿瘤的容积转移常数(Ktrans)、速率常数(Kep)、细胞外细胞外体积分数(VE)、血浆分数(VP)和表观扩散系数(ADC)。确定这些小肾细胞癌影像学参数与肿瘤大小和 RNA 表达之间的相关性。
肿瘤大小与 Kep 显著相关,与 VE、VP、ADC 和标志性血管生成呈负相关。CCP 评分与 Ktrans 和 Kep 显著负相关。ccA 肿瘤在 MRI 上倾向于出现假包膜。
肿瘤大小与低灌注相关,但与基于基因组分析的预后因素无关。成像参数(如 Ktrans 和 Kep)和肿瘤特征(如假包膜)可能使小肾细胞癌的基因风险分层成为可能。